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Abstract 
Previous research has showed that AMPA receptor can be used as a molecular target for anti-epileptic 
drugs, and there is evidence of an inhibitory effect of several fatty acids on AMPA receptor, for example, 
Decanoic Acid (DA), 4-Ethyl Octanoic Acid (4EOA) and 4-Butylcy Cloheaxne Carboxylic Acid 
(4BCCA). However, as NMDA receptor and AMPA receptor are quite similar in structures and are 
widely distributed in CNS, there is a concern on whether the three fatty acids also have an effect on 
NMDA receptor, and NMDA receptor inhibition may result in some unwanted side effects, such as 
hallucinations, nightmares, and memory loss. Two-electrode voltage clamp was performed on the 
oocytes of Xenopus Laevis expressing the NMDAR subunit GluN1/N2A, to record agonist evoked 
inward currents generated from oocytes exposed to different concentrations of fatty acid solutions. On 
further examination it was found that all of the three acids have some inhibitory effect on NMDA 
recceptor, and seem to act as non-competitive antagonists. The 4EOA has the strongest inhibition effect 
on NMDA receptor, followed by 4BCCA and DA. However, the three fatty acids only have a clear 
inhibitory effect when the concentration of the corresponding fatty acid is higher than 500 µM, which is 
considered high for clinical use. Moreover, the fatty acids tested had a stronger inhibitory effect on 
NMDA receptor containing the GluN1/N2B subunits. 
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1. Introduction 
1.1 Glutamate  
In the nervous system, the proportion of neural glial cells (mainly astrocytes) and neurons is about 10:1. 
Astrocytes are located between neurons and blood capillaries, which plays an important role in the 
formation of blood-brain barrier (Brusilow et al., 2010). Under normal conditions, the concentration of 
glutamate in the cytoplasm of neurons is 5-10mM, in extracellular is 0.2-20 μM, there is a huge 
difference between extracellular glutamate concentration and intracellular glutamate concentration 
(Featherstone, 2010). During synaptic transmission, nerve impulses are transmitted to nerve synapses 
and nerve endings are depolarized, and synaptic vesicles are released from neurons (i.e., exocytosis) by 
fusion of synaptic vesicles and plasma membranes. The release of glutamate from vesicles could 
increase the concentration in synaptic gap from resting 1μM to 1.1mM, and maintained peak time is 
about 1.2ms (Brusilow et al., 2010). All types of glutamate receptors acting on the postsynaptic 
membrane, will transmit nerve impulses and play a physiological role. Meanwhile, negative feedback 
regulation is triggered, glutamate uptake by glutamate transporters on astrocytes membranes, as glial 
cells have strong glutamate uptake ability, and contain glutamine synthetase, which can transform 
glutamate into glutamine, and then transport into the cytoplasm of presynaptic nerve terminals and 
produce glutamate by deamination of glutamine (Purves & Williams, 2001). At the same time, some 
glutamate are catalyzed by glutamate decarboxylase to produce the GABA with inhibition effect 
(Petroff, 2002). Consequently, glutamate are transported into vesicle lumen by glutamate transporters 
located on the vesicles, and glutamate are finally stored in the vesicle. In resting, neuron, glutamate is 
stored in the synaptic vesicles of nerve endings in very small membrane-bound organelles. 
Therefore a “glutamate-glutamine cycle” is formed between neurons and glial cells (Purves & Williams, 
2001). 
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Figure 1. The Glutamate-Glutamine Cycle 
 
Glutamate are removed by the glutamate transporters on both glial cell and presynaptic terminals. 
Glutamate are converted to glutamine in glial cell by glutamine synthetase, and glutamine are 
converted to glutamate in presynaptic terminals by glutaminase once they receive glutamine. The 
supply of glutamate is in maintained by the glutamate-glutamine cycle (Purves & Williams, 2001).  
Glutamate is a very important neurotransmitter in the brain as they serve for almost all excitatory 
neurons (Stahl, 1997). There are 2 main categories of glutamate receptors, which are inotropic 
glutamate receptors and metabotropic glutamate receptors. Inotropic glutamate receptors fall into 3 
types of receptors, which are NMDA receptor, AMPA receptor and kainite receptor. 
1.2 AMPA Receptor  
AMPA receptor dysfunction can lead to a variety of neurological damage and mental disorders. The 
structure and function of AMPA receptor, and the mechanism of epilepsy is reviewed. 
AMPA receptor is a tetramer composed of 4 subunits GluAl-GluA4 (also called GluR1-GluR4), which 
originated from the synthesis of rough endoplasmic reticulum, each subunit has 1 large N-terminus, 3 
transmembrane domains, 1 transmembrane ion pore and 1 C-terminus (Shi, 1999). GluA2 always 
makes the AMPA receptors impermeable to Ca2+, however, AMPA receptors are highly permeable to 
Ca2+ if they only composed of GluA1/3/4 (Han et al., 2017). 
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Figure 2. The Structure of GluA2 Subunit of AMPAR 
http://www.bristol.ac.uk/synaptic/receptors/ampar/ 
 
The GluA2 subunit is typically composed of the 3 domains, the extracelluar N-terminus and 
intracellular C-terminus. GluA2 governs the AMPA receptor’s permeability to Ca2+. 
AMPA receptor is mainly mediated by the central nervous system of the fast excitatory synaptic 
transmission, and they are essential in synaptic transmission efficiency, neuronal integration and 
synaptic plasticity (Gouaux, 2004). AMPA receptor is ligand gated ion channel receptor, receptor ion 
channel opens only when excited, and only monovalent cation can flow through the ion channel, such 
as k+ and Na+. Influx of extracellular Na+ leads to depolarization of postsynaptic membrane, inducing 
rapid EPSP (excitatory postsynaptic current), and then participating in excitatory synaptic transmission 
(Lajeunesse et al., 2012). At the same time, membrane depolarization resulted from AMPA receptor 
removes the Mg2+ in the channel of NMDA receptor, leads to activation of NMDA receptor. Once 
NMDA receptor channel opens, the influx of Ca2+ will increase the intracellular Ca2+ concentration, 
triggering a series of biochemical reactions, and even results in LTP (long-term potentiation) 
(Nishiyama & Hanaoka, 2000).  
The sudden increase in the excitability of excitatory neurons results an uncontrolled spontaneous 
abnormal discharge, and it associated with symptoms of recurrent seizures (Chang & Lowenstein, 
2003). Over-activation of AMPA receptor may has been associated with acute nerve injury, such as 
hypoxia-ischemia, hypoglycemia or persistent seizures, and “GluR2 hypothesis” has been suggested: 
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Down-regulation of GluA2 subunit gene expression in neurons made them more susceptible to toxicity 
of endogenous glutamate (Pellegrini-Giampietro, 1997). KA (Kainic Acid) has been reported to 
induced epilepsy in hippocampal CA3 region, and decrease the expression of GluA2, which is 
subsequently by GluA1 and GluA3 in the AMPA receptor channel. As a result, the permeability of 
AMPA receptor to Ca2+ increases, thus causing damage to hippocampal neurons (Sommer et al., 2001). 
Moreover, Friedman (2003) demonstrated damage to hippocampal CA3 neurons, but not to CA1 
neurons in a rat model of KA-induced epilepsy. In contrast, the injection of AMPAR antagonist 2, 
3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2, 3-dione (NBQX) exerted protective effects. 
This has been corroborated by Yamashita et al. (2004) who showed that AMPAR antagonist 
2-[N-(4-chlorophenyl)-N-methylamino]-4H-pyrido [3, 2-e]-1, 3-thiazin-4-one (YM928) could also 
control seizures in KA-induced epilepsy. Similarly, the noncompetitive AMPA receptor antagonist 2, 
3-benzodiazepine (GYKI52466) could mitigate the seizures, shorten their duration, and exert an 
anticonvulsive effect (Rakovska et al., 2002). Based on these previous findings, AMPARs, particularly 
the GluR2 subunit, are involved in the pathogenesis of epilepsy, while AMPAR antagonists may be 
candidates for an effective epilepsy treatment. 
1.3 NMDA Receptor 
NMDA receptor is also an ionotropic glutamate receptor, which is mainly involved in the development 
of neural circuits in the refinement and trigger a variety of forms of synaptic plasticity (Li & Tsien, 
2009). In recent years, evidence has shown that the subunits of NMDA receptor have complex 
physiological and pharmacological properties. The number, distribution and subunit composition of 
NMDA receptors are not static, it changes in cell specificity and synapse specificity in the process of 
development and neuronal activity (Paoletti et al., 2013). The bidirectional change of the NMDA 
receptor is the basis of the remodeling of synaptic plasticity, and the abnormal regulation can lead to 
the occurrence of mental disorders, such as memory deficits, hallucinations, schizophrenia, and so on 
(Paoletti et al., 2013). 
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Figure 3. The Structure of NMDA Receptor 
 
This NMDA receptor consisting of GluN1 and GluN2 subunit. Both glutamate and glycine are needed 
to active the NMDA receptor. The Mg2+ will block the NMDAR ion channel at resting membrane 
potential, only the depolarization of postsynaptic nerve cell will remove the Mg2+ ion, and allow the 
Ca2+ current to flow through the NMDA receptor. 
The activation requirement of NMDA receptor is special as its ion channel needs 2 kinds of agonists to 
activate, namely glutamic acid (glutamate) and glycine (Cull-Candy et al., 1998), with the binding site 
of glutamate lying on GluN2 subunit and binding site of glycine on GluN1 subunit. Researches by Yao 
(2006) indicated that GluN3 subunit was with high affinity to glycine, which proved that glycine could 
activate GluN3 subunit. 
The density of NMDA receptor subunit in different part of brain tissue is different with significant 
difference of density at various developmental stages GluN1 subunit was widely distributed in CNS 
(central nervous system). GluN2B subunit was widely distributed in neonatal brains and GluN2D 
subunit widely spread in neonatal brain stem. The content of the two gradually fell down with newborn 
growth and development process. The GluN2A subunit which is mainly located in hippocampus and 
cortex while GluN2C subunit was rich in cerebellum (Cull-Candy et al., 1998). By observing the ultra 
structure of NMDA receptor, people such as Radley et al. (2007) found that GluN2B subunit mainly 
located in thalamus and amygdala of adult brains. 
GluN3A mRNA was expressed most in the cerebral cortex of 1 week newborn baby and then its 
expression fell down. By applying ISH (In Situ Hybridization) and immune his to chemistry method, 
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Chatterton et al. (2002) found that GluN3A subunit was widely distributed in central nervous system 
while GluN3B subunit mainly could been seen in medulla spinalis and the motor neuron in brain stem. 
NMDA receptor is a unique ligand-gated ion channel as its activation needs both glutamate and glycine. 
Normally NMDA receptor consist of two GluN1 subunits and GluN2 subunits is highly permeable to 
Ca2+. Meanwhile, NMDA receptor’s high affinity to endogenous channel blocker Mg2+ makes it have 
voltage dependent blocking characteristics (VanDongen, 2009). Thus, the cell signaling induced by 
NMDA receptor played an important role in neuronal growth and regulation, neuronal dendrite and 
axon structure development, synaptic plasticity, learning and memory, etc. Liu et al. (2007) used 
Western blotting method and found that on cerebral cortical neurons, the NMDA receptor containing 
GluN2A subunit on the synapse and outside of the synapse could facilitate neuronal growth and protect 
neuronal damage. 
Under physiological conditions, with postsynaptic membrane staying in resting stage, the presence of 
Mg2+ ion in NMDA receptor ion channel can block Ca2+ influx as the ion channel gate is voltage 
dependent. Due to high permeability of GluN2 subunit to Ca2+, the activation of NMDA receptor by 
endogenous glutamic acid can leads to Ca2+ influx and Ca2+ will mediate a series of cell signaling 
pathways. When the amount of Ca2+ in postsynaptic neuron cytoplasm greatly increases, the 
postsynaptic membranes will be depolarized and action potential will be generated by postsynaptic 
neurons, all of these will lead to LTP (Long Term Potentiation). LTP long-term enhancing synaptic 
transmission efficiency is considered as the basis of learning and memory, while LTD (Long Term 
Depression) will reduce synaptic transmission efficiency (TSUMOTO, 1992). In rat hippocampal slices, 
Berberich et al. (2007) found that following application of high frequency stimulation, GluN2A and 
GluN2B worked together to facilitate generation of LTP; While using low frequency stimulation, either 
GluN2A or GluN2B subunit could induce LTP generation.  
1.4 Aims and Hypothesis 
Recently, more researchers focused on the effect of fatty acids on these glutamate receptors. The fatty 
acids are carboxylic acids with hydrocarbon chain and terminal carboxyl group (Barnes, 1959). 
Decanoic acid is a saturated fatty acid. 4EOA and BCCA have been chemically synthesized as novel 
compounds based on the structure of DA. 
Chang et al. (2016) suggested that there was inhibitory effect of Decanoic Acid (DA) on AMPA 
receptor, with IC50=1.16mM on GluA1/2 and IC50=0.52mM on GluA2/3. It stated that DA (Decanoic 
Acid) acted as an non-competitive antagonist on AMPA receptor, and DA may help to control seizure 
through direct AMPA receptor inhibition. 4EOA (4-Ethyloctanoic Acid) also showed an inhibitory 
effect on AMPA receptor, with IC50 around 0.65mM on GluA2/A3. 4BCCA (4-Butylcyclohexane 
Carboxylic Acid) did an inhibitory effect on AMPA Receptor as well, with IC50=1mM for GluA1/2, 
and IC50=0.5mM for GluA2/3. 
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Figure 4. The Structure of the 3 Fatty Acids Used in the Experiment 
 
The left top is 4BCCA (4-Butylcyclohexane Carboxylic Acid), the right top is 4EOA (4-Ethyloctanoic 
Acid) and the bottom one is DA (Decanoic Acid). 
As NMDA receptor is essential for normal CNS function, disruption of NMDA receptor will affect CNS 
adversely, with the symptoms of memory loss, breathing and locomotion deficits, hallucinations and 
nightmares (VanDongen, 2009). Therefore, there is a concern arised on whether inhibition of AMPA 
receptor during epilepsy treatment will in turn affect the NMDA receptor, since both AMPA receptor and 
NMDA receptor are glutamate receptors and they are somehow similar in structure and distribution. The 
aim of this experiment was to investigate whether the 3 acids mentioned before have any inhibitory effect 
on NMDA receptor, to avoid the side effects when they used as AMPA receptor antagonist for epilepsy 
treatment, and to examine the sensitivity of GluN2A and GluN2B subunits to these fatty acids 
respectively. The null hypothesis was there was no any inhibitory effect resulted from the 3 fatty acids on 
NMDA receptor, and no difference between sensitivity of GluN2A to the fatty acids and sensitivity of 
GluN2B. The alternative hypothesis was that there was an inhibitory effect of the fatty acids on the 
resulted from the 3 fatty acids on NMDA receptor, and there was a difference between sensitivity of 
GluN2A to the fatty acids and sensitivity of GluN2B. The null hypothesis was retained when p>0.05, and 
the null hypothesis was rejected when p<0.05. 
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2. Method 
2.1 Peeling of the Oocytes and RNA Injection 
The Xenopus laevis are considered ideal for studying the expression of ion channels and receptors due to 
their versatile expression system (Bros, 2010). Thus, we used the oocytes of X. Laevis to express NMDA 
receptors.  
First, the thin membrane composed of blood capillaries covering the oocytes was removed using forceps 
under the microscope in order to facilitate the RNA injection. To inhibit the release of glutamate from the 
oocytes, which would increase their death, the oocytes were incubated in 24-well plates with 1X Bath’s 
solution (88 mM NaCl, 1 mM KCl, 2.3 mM NaHCO3, 15 mM Tris HCl, 0.82 mM MgCl2, 0.77 mM 
CACl2 with pH adjusted to 7.4 by NaOH [4 M], added to 50 IU/mL penicillin and 50 μg/mL 
streptomycin) containing 500 μM of (2R)-Amino-5-Phosphonovaleric Acid (APV), which is a glutamate 
antagonist. A total of 2 mL per well were used for the incubation.  
The RNA was stored at -79 °C until used. A total of 2 μL of a mixture of NMDAR subunits GluN1 and 
GluN2A RNA (the ratio of GluN1: GluN2A is 1:1, the concentration of RNA used was 5 ng/μL) was 
used for each set of experiment. A total of 46 nL of RNA were injected into one oocyte through the 
injection pipette (Harvard Apparatus catalogue NO.690133) cut by an electrode puller (Narashinge). 
Each injected oocyte was placed in an individual well, and the plate was incubated at -15 °C for 1-2 days 
to allow the RNA to express the NMDA receptors. 
2.2 Preparation of the Solutions and Fatty Acids 
Glycine and glutamate were used at 50 mM and 100 mM, respectively. A total of 1.72 g of DA/4EOA 
(molecular weight, 172 g/mol) were diluted with 10 mL Dimethyl Sulfoxide (DMSO) resulting in 1 M 
DA/4EOA solution. The 1M 4BCCA was previously prepared by others. Ringer’s solution (1X) was 
diluted from 10X Ringer’s stock solution (1.15 M NaCl, 25 mM KCl, 100 mM 
4-[2-hydroxyethyl]-1-piperazineethanesulfonic acid [HEPES]). Given that NMDARs are pH-sensitive, 
the pH was adjusted to 7.35 with 4 M NaOH. Subsequently, to enable a smoother response current and 
reduce the current fluctuation, 1.8 mM of BaCl2 were added to every 1L 1X Ringer’s solution. The stock 
concentration of the fatty acids included in 4BCCA, DA and 4 EOA was 1 M. 
2.3 Two Electrode Voltage Clamp (TEVC) 
During the electrophysiological measurements, the injected oocyte was removed from the plate each 
time and placed in the recording chamber immersed with buffer (mixture of Ringer’s/glutamate/glycine 
solution) to acquire the electrophysiological recordings (Axon Instrument DIGIDATA 1322A). The 
electrodes were made from borosilicate glass (GC150TF7.5, Harvard Apparatus) and generated by the 
electrode puller (Narashinge). Electrodes were filled up with 300 mM KCl, and the voltage was set to 
-40 mV. The data were only recorded when the current produced by the oocytes was less than 0.60 µA. 
Eight tubes linked to the recording chamber were refilled with different solutions and were controlled 
by a valve commander (ALA Scientific Instruments). Data were subsequently processed in WinEDR 
software v3.7.5 (University of Strathclyde Glasgow, UK). 
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2.4 Wild-Type GluN2A Dose Response Curve (Control)  
Fresh 1X Ringer’s solution was added to the first tube linked to the recording chamber. In the second 
tube, 100 µL Ringer’s were mixed with 0.1 μM glutamate and 50 μM glutamate. The glutamate 
concentrations in tubes 3 to 8 were 0.3 μM, 1 μM, 3 μM, 10 μM, 30 μM and 100 μM, respectively. The 
concentration of glycine remained constant. The current at each glutamate concentration was measured. 
The difference of the response current was calculated between the baseline and each glutamate 
concentration, and was presented as a percentage to the maximum response. Approximately 6-10 
oocytes were randomly selected from the oocytes pool at 2 weeks to record the current for one 
complete set of wild-type GluN2A dose response curve. A dose response curve was plotted as the 
normalized response (%) against the glutamate concentration (μM) by using Igor Pro software v6.1 
(WaveMetrics). 
2.5 The Calculation of the Half Maximal Effective Concentration (EC50) Curves 
2.5.1 The EC50 Curve for 4BCCA 
The glycine/glutamate/1X Ringer’s solution was mixed with 1 mM 4BCCA and placed into tubes to 
examine the EC50 curve. The last tube was devoid of 4BCCA to compare the difference in the current 
recorded with and without fatty acid. A total of 6-10 oocytes were taken randomly from the oocytes pool 
at 2 weeks to record the current for one complete set of 1 mM 4BCCA EC50 curve experiment. The dose 
response curve was plotted in the same way for the control. The EC50 value was calculated by using the 
Igor Pro software v6.1. 
2.5.2 The EC50 Curve for DA 
The same above-mentioned procedure was repeated by using 500 µM DA, 750 µM DA and 1 mM DA. 
2.5.3 The EC50 Curve for 4EOA 
The same above-mentioned procedure was repeated by using 500 µM 4EOA, 1 mM 4OEA, 2 mM 4EOA 
and 3 mM 4EOA. 
2.6 The Half Maximal Inhibitory Concentration (IC50) Curve for 4EOA at 3 µM Glutamate 
The glycine/glutamate/1X Ringer’s solution was supplemented with 3 μM glutamate and 50 μM glycine, 
and the mixture was placed in tube 2-6 with 4EOA at 100 μM, 300 μM, 1 mM, 3 mM and 5 mM, 
respectively. The IC50 value was calculated by using the Igor Pro software v6.1. 
2.7 The DMSO Control 
For the DMSO control recording, 100 µL DMSO replaced the fatty acid in the glycine/glutamate/1X 
Ringer’s solution. The aim behind performing the DMSO control was to verify whether there was any 
difference between 1 mM fatty acid dissolved in DMSO and DMSO alone, and to ensure that DMSO had 
no effect on the NMDA receptors. 
2.8 The GluN1/N2B NMDA Receptor Subunits 
Instead of mixture of GluN1 and GluN2A, 2 µL of mixture of GluN1 and GluN2B subunits were 
injected into the peeled oocytes (the ratio of GluN1: GluN2B is 1:1, the concentration of RNA used 
was 5 ng/μL). The same measurements as for the AMPA receptor subunits were performed, including 
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the control, 4BCCA EC50 curve (100 µM and 1 mM 4BCCA), DA EC50 curve (500 µM and 1 mM 
DA), 4EOA EC50 curve (200 µM and 3 mM 4EOA) on the oocytes with GluN1/N2B subunits. 
2.9 Statistical Analysis 
The electrophysiological recording data were arranged using Excel 2013. All data we analyzed with 
SPSS software using paired and unpaired t-test. Statistical significance was considered at p<0.05. 
When p<0.05, the null hypothesis was rejected. When p>0.5, null hypothesis was accepted.  
 
3. Result 
After TEVC (Two Electrode Voltage Clamp) had been performed on the oocytes of Xenopus laevis, a 
electrophysiological recording was obtained to indicate the effect of glutamate on NMDA receptor. 
4BCCA was applied first on the oocytes of Xenopus laevis, as 4BCCA was available in stock first at the 
beginning of the experiment. Also, 4BCCA had the lowest IC50 on AMPA receptor (GluA2/3) among 
the 3 fatty acids we are going to test, and it would be easier to compare the effect of 4BBCA with the 
other two. 
3.1 The Effect of Different Concentrations of 4BCCA on NMDA Receptor 
 
 
Figure 5. Example of Standard Electrophysiological Recordings for the Effect of 1mM 4BCCA on 
NMDA Receptor (GluN1/2A) 
 
Glycine concentration was kept at 50μM, glutamate concentration varied from 0.3μM, 1μM, 3μM, 
10μM, 30μM, 100μM. 4BCCA concentration was 1mM. The effect of 4BCCA was investigated by 
comparing 100μM glutamate with 1mM 4BCCA and without any 4BCCA. 
The effect of 1mM 4BCCA was indicated by a reduction in the current. It was compared latterly with 
the standard electrophysiological recording (without any addition of fatty acids) to show the difference 
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the two recordings, and therefore, to get the glutamate dose response curve for each one, and in the end 
to conclude the effect of 1mM 4BCCA by their normalised response at 100μM glutamate and EC50 
value. When examine the effect of 1mM 4BCCA on gluN2A and make the glutamate dose response 
curve to get the EC50 value, the 1mM 4BCCA glutamate dose response curve was not only compared 
with the control glutamate dose response curve (named control for N2A), but also compare with the 
DMSO control glutamate dose response curve (named DMSO control for N2A), where DMSO is used 
for preparing and diluting the fatty acid. Compare the EC50 value and normalised response at 100μM 
glutamate between 1mM 4BCCA and DMSO control could help conclude if the fatty acid itself could 
be the independent variable that exert an inhibitory effect on NMDA receptor (GluN1/GluN2A), or the 
DMSO solution could also had an inhibitory effect on NMDA receptor. 
 
 
Figure 6. The Effect of DMSO Control and 1mM 4BCCA NMDARs (GluN1/N2A Subunits) 
 
The DMSO solution used for making the fatty acid solutions were examined on whether they had any 
effect on the normalised response. The volume of DMSO solution added for making this dose response 
curve was same as the amount of DMSO in 1mM 4BCCA. The error bars were ± SEM. N=6-10. 
The DMSO solution itself had no effect on NMDA receptor (GluN1/N2A), whether on the maximum 
normalised response at 100μM glutamate (p=0.079), or EC50 (p=0.599). However, the 1mM 4BCCA 
made an inhibitory effect on NMDA receptor (GluN1/N2A) (for the details see next figure), and 
therefore the inhibitory effect was completely due to the presence of the fatty acid but not the DMSO 
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solution. 
 
 
Figure 7. The Effect of Different Concentrations of 4BCCA on NMDA Receptor (GluN1/N2A 
Subunits) 
 
The single dose response curve of 100μM, 250μM, 500μM, and 1mM 4BCCA at 0.3μM, 1μM, 3Μm, 
10μM, 30μM, 100μM glutamate compared to the wild type GluN2A (control). The error bars were ± 
SEM. N=6-10. 
In fact, 4 different concentrations of 4BCCA were used to test the inhibitory effect of 4BCCA on 
GluN1/N2A subunits, from 100μM, 250μM, 500μM to 1mM. The lowest concentration of 4BCCA 
applied was determined by the point which resulted in no change in the normalised response at 100μM 
glutamate, and the highest concentration of 4BCCA applied was determined by the solubility of the 
fatty acid, as the 4BCCA solution could not be used when there was a precipitate formation. 
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Figure 8. The Comparison between Wild Type (GluN2A) and Difference Concentrations of 
4BCCA on Normalised Response at 100μM Glutamate (μM), Rate and EC50 (μM) (± SEM) 
 
The 0μM 4BBCA represented the wild type (GluN2A).  
Both 100μM and 250μM 4BCCA had no any effect on NMDARs (GluN1/N2A) with p=0.205 and 
p=0.136 respectively. 500μM 4BCCA reduced the response at 100μM glutamate by 15.6% (p=0.017). 
1mM showed the strongest inhibitory effect and reduced the response at 100μM by 38.4% (p<0.001). 
Therefore, only 500μM 4BCCA and 1mM 4BCCA showed inhibitory effect on NMDARs (GluN1/N2A 
subunits), and the inhibitory effect became stronger when the concentration of 4BCCA increased. There 
was no change in the EC50 when comparing different concentrations of 4BBCA and wild type 
(GluN2A). The EC50 showed no significant change between different concentrations of 4BCCA and 
control (GluN2A) as p>0.05 for all the four concentrations.  
After trying GluN1/N2A subunit, the effect of 4BCCA was also investigated on GluN1/N2B subunits, 
to further illustrate the sensitivity of Glu2A and GluN2B subunits to 4BCCA, as the NMDA receptors 
in CNS contains both GluN1/N2A and GluN1/N2B. 
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Figure 9. The Effect of Different Concentrations of 4BCCA on NMDA Receptor (GluN1/N2B 
Subunits) 
 
The single dose response curve of 100μM and 1mM 4BCCA at 0.3μM, 1μM, 3Μm, 10μM, 30μM, 
100μM glutamate compared to the wild type GluN2B (control). The error bars were ± SEM. N=6-10. 
 
 
Figure 10. The Comparison between Wild Type (GluN2B) and Difference Concentrations of 
4BCCA on Normalised Response at 100μM Glutamate (μM), Rate and EC50 (μM) (± SEM) 
 
The 0μM 4BBCA represented the wild type (N2B).  
Only the lowest and highest concentration of 4BCCA applied on GluN1/N2A, were used to applied on 
GluN1/GluN2B, which were 100μM and 1mM 4BCCA respectively, as the main aim of this procedure 
was to investigate the difference in 4BCCA inhibitory effect between GluN1/N2A and GluN1/N2B. 
The 100μM 4BCCA slightly decreased the response at 100μM glutamate by 7.5% (p=0.004), and 1mM 
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4BBCA decreased the response at 100μM glutamate by 41.8% (p<0.001). The EC50 of 100μM 4BCCA 
showed a decrease of 0.41 μM compared to the control (GluN2B) (P=0.037), and the EC50 of 1mM 
4BCCA showed a decrease of 0.33 μM compared to the control (GluN2B) (p=0.036). 
 
 
Figure 11. The Comparison of the Percentage of Reduction in Normalised Response for 100μM 
and 1mM 4BCCA between GluN1/N2A and GluN1/N2B Subunits 
The difference between normalised response at 100μM 4BBCA (GluN2A) was compared to the wild 
type (GluN2A) to get the percentage of reduction in normalised response for 100μM 4BCCA 
(GluN2A). 
** indicated that p<0.05. The error bars were ± SEM. N=6-10. 
 
There was no significant inhibitory effect of 100μM 4BCCA on GluN2A subunit, however, it did show 
to slightly decrease the normalised response on GluN2B subunit. Moreover, 1mM 4BCCA also showed 
a stronger inhibitory effect on GluN2B than GluN2A. Therefore, it may concluded that GluN2B was 
more sensitive than GluN2A subunits to 4BCCA. 
3.2 The Effect of Different Concentrations of DA on NMDA Receptor  
Since DA and 4BCCA are similar in chemical structure’ after doing the 4BCCA glutamate dose 
response curve, different concentrations of DA were applied on the on the oocytes of Xenopus laevis to 
get the electrophysiological recording, and therefore to plot the DA glutamate dose response curve by 
similar procedure. 
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Figure 12. The Effect of Different Concentrations of DA on NMDA Receptor (GluN1/N2A 
Subunits) 
 
The single dose response curve of 500μM, 750μM and 1mM DA at 0.3μM, 1μM, 3μM, 10μM, 30μM, 
100μM glutamate compared to the wild type GluN2A (control). The error bars were ± SEM. N=6-10. 
Unlike 4BCCA, there were only 3 different concentrations of DA were used to test the inhibitory effect 
of 4BCCA on GluN1/N2A subunits, which were 500μM, 750μM and 1mM. The lowest concentration 
of DA applied was determined by the point which resulted in no change in the normalised response at 
100μM glutamate, and the highest concentration of DA applied was determined by the solubility of the 
fatty acid, as the DA solution could not be used when there was a precipitate formation. The range of 
DA concentration was smaller compared to 4BCCA, as DA did not result in a decrease of normalised 
response at 100μM glutamate when it concentration was as high as 500μM. 
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Figure 13. The Comparison between Wild Type (GluN2A) and Difference Concentrations of DA 
on Normalised Response at 100μM Glutamate(μM), Rate and EC50 (μM) (± SEM) 
 
The 0μM 4BCCA represented the wild type (GluN2A).  
Both 500μM and 750μM DA had no effect on NMDA receptor (GluN1/N2A) with p=0.916 and 
p=0.054 respectively. DA only showed an inhibitory effect when the concentration reached 1mM and 
the normalised response at 100μM glutamate was decreased by 13.2% (p=0.041). The change in EC50 
was not statistical significant at 500μM DA (p=0.095). The EC50 decreased by 49.2% at 750μM DA 
(p=0.002) and by 29.6% at 1mM DA (p=0.018) compared to wild type (GluN2A). 
 
 
Figure 14. The Effect of Different Concentrations of 4BBCA on NMDARs (GluN1/N2B Subunits) 
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The single dose response curve of 100μM and 1mM 4BCCA at 0.3μM, 1μM, 3Μm, 10μM, 30μM, 
100μM glutamate compared to the wild type GluN2B (control). The error bars were ± SEM. N=6-10. 
 
 
Figure 15. The Comparison Between Wild Type (GluN2B) and Difference Concentrations of DA 
on Normalised Response at 100μM Glutamate (μM), Rate and EC50 (μM) (± SEM) 
 
The 0μM DA represented the wild type (GluN2B).  
The normalised response at 100μM glutamate had been decreased by 24.0% at 500μM DA (p<0.001) 
and by 35.0% at 1mM DA (p<0.001) on GluN2B subunit. However, the EC50 did not show any 
significant change either at 500μM DA (P=0.243) or 1mM DA (P=0.556). 
Only the lowest and highest concentration of DA applied on GluN1/N2A, were used to applied on 
GluN1/GluN2B, which were 500μM and 1mM DA respectively, as the main aim of this procedure was 
to investigate the difference in DA inhibitory effect between GluN1/N2A and GluN1/N2B. 
 
 
Figure 16. The Comparison of the Percentage of Reduction in Normalised Response for 5000μM 
and 1mM DA between GluN1/N2A and GluN1/N2B Subunits 
** indicated that p<0.05. The error bars were ± SEM. N=6-10. 
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Although 500μM DA did not have any inhibitory effect on GluN2A subunits, it did have a relatively 
strong inhibitory effect on GluN2B with a 35% reduction in normalised response.  
Also, 1mM DA only decreased the normalised response by 13.2% on GluN2A, but it decreased the 
normalised response by 35.0% at GluN2B. In this way, GluN2B was more sensitive to DA than 
GluN2A. However, it was interesting to find that DA only altered the EC50 when they acted on 
GluN2A subunits, no significant change in EC50 between DA (GluN2B) and control (GluN2B) found.  
3.3 The Effect of Different Concentrations of 4EOA on NMDA Receptor 
4EOA was another fatty acid similar to 4BCCA and DA structure, and it had a relatively low IC50 on 
AMPA receptor (GluA2/3 subunits). The last fatty acid used in this experiment used was 4EOA. 
Different concentrations of 4EOA were applied on the on the oocytes of Xenopus laevis to get the 
electrophysiological recording, and therefore to plot the 4EOA glutamate dose response curve by 
similar procedure. 
 
 
Figure 17. The Effect of Different Concentrations of 4EOA on NMDA Receptor (GluN1/N2A 
Subunits) 
 
 
The single dose response curve of 200μM, 1mM, and 3mM 4EOA at 0.3μM, 1μM, 3Μm, 10μM, 30μM, 
100μM glutamate compared to the wild type GluN2A (control). The error bars were ± SEM. N=6-10. 
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There four different concentrations of 4EOA were used to test the inhibitory effect of 4EOA on 
GluN1/N2A subunits, which were 200μM, 1mM and 3mM. The lowest concentration of 4EOA applied 
was determined by the point which resulted in no change in the normalised response at 100μM 
glutamate, and the highest concentration of 4EOA applied was determined by the solubility of the fatty 
acid, as the EOA solution could not be used for investigating the inhibition effect when there was a 
precipitate formation. The range of 4EOA concentration used was much higher than 4BCCA and DA, 
as the solubility of 4EOA in DMSO solution was higher than 4BCCA and DA, and the 4EOA glutamate 
dose response curve showed that 3mM 4EOA had a relatively strong inhibitory effect on NMDA 
receptor (GluN1/N2A subunits). 
 
 
Figure 18. The Comparison between Wild Type (GluN2A) and Difference Concentrations of 
4EOA on Normalised Response at 100μM Glutamate (μM), Rate and EC50 (± SEM) 
 
The 0μM 4EOA represented the wild type (GluN2A). 200μM 4EOA did not show an inhibitory effect 
on NMDA receptor (GluN1/N2A) with p=0.083. 1mM 4EOA showed an inhibitory effect as the 
normalised response at 100μM glutamate was decreased by 16.2% (p=0.024), and 3mM even showed a 
stronger inhibitory effect as the normalised response was decreased by 41.4% (p<0.001). The change in 
EC50 was not significant for all the 3 concentrations of 4EOA, as p=0.231 for 200μM 4EOA, p=0.080 
for 1mM 4EOA and p=0.811 for 3mM DA.  
Then, as the range for 4EOA concentration used in the experiment was much higher than 4BCCA and 
DA, which from 200 μM to 3mM, and therefore a IC50 graph was plot to examine the IC50 value (The 
main reason for not plotting the IC50 graph for 4BCCA and DA was their small range of concentration). 
IC50 half maximal inhibitory concentration was the concentration of the drug that was required for 
50% inhibition, and it was used to test the effectiveness of the drug’s inhibition effect. The glutamate 
concentration was kept constant at 3μM, which was the EC50 value for control glutamate dose 
response curve.  
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Figure 19. The Inhibitory Dose Response Curve for 4EOA (GluN1/N2A Subunits) 
 
The glycine concentration was kept at 50μM. The glutamate concentration was kept at 3μM. The 4EOA 
concentration varied from 100μM, 300μM, 1mM, 3mM to 5mM. The error bars were ± SEM. n=7. The 
maximum response was 0.97003 ± 0.123, the rate was -1.047 ± 0.867, and the IC50 value was 0.92374 
± 0.322 mM. 
Therefore, 0.92374 ± 0.322 mM 4EOA was required to produce 50% inhibition on NMDA receptor 
(GluN1/GluN2 subunits). 
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Figure 20. The Effect of Different Concentrations of 4EOA on NMDA Receptor (GluN1/N2B 
Subunits) 
 
The single dose response curve of 200μM and 3mM 4EOA at 0.3μM, 1μM, 3μM, 10μM, 30μM, 
100μM glutamate compared to the wild type GluN2B (control). The error bars were ± SDE. N=6-10. 
 
 
Figure 21. The Comparison between Wild Type (GluN2B) and difference Concentrations of DA 
on Normalised Response at 100μM Glutamate (μM), Rate and EC50 (μM) (± SDE) 
 
The 0μM DA represented the wild type (GluN2B).  
There was an inhibitory effect of both 200μM 4EOA and 3mM 4EOA on NMDAR (GluN2B subunits). 
The normalised response of 200μM had decreased by 21.2% (p<0.01) compared to the control 
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(GluN2B). The normalised response of 3mM had decrease by 48.3%, where was a quite strong 
inhibitory effect (p<0.001). However, both 200μM 4EOA and 3mM 4EOA showed no significant 
change in the EC50 (p=0.48 for 200μM 4EOA EC50 and p= 0.19 for 3mM 4EOA EC50). 
Only the lowest and highest concentration of 4EOA applied on GluN1/N2A, were used to applied on 
GluN1/GluN2B, which were 200μM and 3mM 4EOA respectively, as the main aim of this procedure 
was to investigate the difference in 4EOA inhibitory effect between GluN1/N2A and GluN1/N2B. 
 
 
Figure 22. The Comparison of the Percentage of Reduction in Normalised Response for 200μM 
and 3mM 4EOAbetween GluN1/N2A and GluN1/N2B Subunits 
** indicated that p<0.05. The error bars were ± SDE. N=6-10. 
 
It could be obviously seen that both 200μM and 3mM 4EOA exerted an inhibitory effect on N2B, but 
only 3mM 4EOA showed an inhibitory effect on GluN2A. Also, 3mM 4EOA induced a relatively 
stronger inhibitory effect on GluN2B (48.3%) compared to GluN2A (41.4%). In addition, there was no 
significant change of EC50 by all the concentration 4EOA tested on either GluN2A or GluN2B 
subunits. The main difference was the normalised response. Therefore, GluN2B subunits was more 
sensitive to 4EOA than GluN2A subunits. 
3.4 Comparing the 3 Fatty Acids 
All of the 3 fatty acids used in the experiment showed an inhibitory effect on NMDA receptor (both 
GluN2A and GluN2B subunits) were considered as non-competitive antagonist as they mainly reduce 
the magnitude of the maximal normalised response but not increase the EC50.  
Among the 3 fatty acids, 4EOA was the strongest antagonist as it only stopped to exert an inhibitory 
effect on NMDA receptor (Glu2A) when the concentration was 200μM, and there was still an 
inhibitory effect on NMDA receptor (Glu2B). 4BCCA had a relatively weaker inhibitory effect, it 
showed an inhibitory effect on NMDA receptor (GluN2A) when the concentration ≥ 500μM. DA had 
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the weakest inhibitory effect on NMDA receptor (GluN2A) as it only showed inhibitory effect when 
the concentration greater than 750μM. Moreover, 4EOA could dissolve in the Ringer’s solution when 
the concentration higher than 3mM, but DA and 4BBCA could only dissolve in the Ringer’s solutions 
when their concentration was 1mM.  
GluN2B subunits were more sensitive to the 3 fatty acids used in the experiment than GluN2A subunits, 
which indicated by a larger percentage of reduction in normalised response found in GluN2B compared 
to GluN2A. 
 
4. Discussion 
4.1 Fatty Acids Act as Non-Competitive Antagonists of NMDA Receptor 
NMDA receptor was coupled with calcium channel to form NMDA receptor/calcium channel 
complexes which were mainly distributed in cerebral cortex, hippocampus and amygdala, and 
secondarily distributed in midbrain, thalamencephalon and cerebellum (Radley et al., 2007). It had 
been proved that NMDA receptor had at least 5 pharmacologically independent binding sites: TBS 
(Transmitter Binding Site), GBS (Glycine Binding Site) and zinc ion binding site, which were located 
on receptor surface; magnesium ion binding site and PCP (Phencyclidine) binding site, which were 
located in ion channel. Drug could directly act on these binding sites to influence the function of 
NMDA receptor (Monaghan, 1989). 
Antagonists are drugs that occupy the receptor but do not elicit a response, to prevent the effect of 
agonists. Competitive antagonists inhibit agonists by competing at the orthosteric site binding site 
(same binding site), but non-competitive antagonists bind to allosteric binding site (alternative binding 
site) (Smiley, 2005). All the three fatty acids used in this experiment (4BCCA, DA and 4EOA) are 
shown to have inhibitory effects on NMDARs were recognised as non-competitive antagonist as they 
resulted in a decrease in magnitude of maximal response, without increasing EC50. For instance, if the 
normalised response at 100 μM glutamate was assumed as the maximal response, 1mM 4BCCA 
reduced the maximal response by 38.4% for GluN1/N2A subunits, and 41.8% for GluN1/N2B subunits. 
1mM reduced maximal response by 13.2% and 35% for GluN1/N2A and GluN1/N2B subunits 
respectively. 3Mm 4EOA reduced the maximal response by 41.4% and 48.3% for GluN1/N2A and 
GluN1/N2B subunits respectively. All the glutamate dose response curve of the three fatty acids did not 
show a significant increase of EC50, as they might work on the allosteric site of the NMDA receptor, 
and the bond between the active site and the fatty acids used were completely or nearly irreversible 
(Rogawski, 1992). 
The mechanism of DA, 4BCCA and 4EOA inhibiting NMDA receptor was unknown, but they might 
work on the PCP binding sites, as PCP binding sites are the considered as allosteric binding site where 
the agonist glutamate do not bind to. With chemical name of N-1-Phenylcyclohexyl-Piperidine (PCP), 
phencyclidine was a dissociative anesthetic applied clinically the earliest. When it produced anesthetic 
action, the patient showed mental and behavior disorder, hence it was prohibited from clinical use for a 
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long time (Morris & Wallach, 2014). However, the mental and behavior disorder caused by it aroused 
attention of neuroscientist. Anis et al. (1983) firstly stated that PCP and ketamine could selectively 
reduce neuronal excitability in spine of rats and cats caused by NMDA receptor activation. More 
widely and deeply research has been performed following Anis’s work, to investigate the relationship 
between action of these drugs and NMDA receptor. Antagonists with stronger action and higher 
selectivity such as TCP, MK-801 (Di-zocilpine) and its derivative ADC1 were finally synthesized 
(Kovacic & Somanathan, 2010). The inhibitory effect of these drugs on NMDA-R was non-competitive, 
large-dose NMDA and glutamate still could not reverse their action, so they were called 
non-competitive NMDA receptor antagonists (Hillhouse et al., 2015).  
Research on radio receptor assays found that the PCP drugs did not influence binding of (3Н-Glu) and 
(3Н)-СРР, indicating that they did not act on TBS (Theta Burst Stimulation) of NMDA receptor, while 
NMDA-R agonist СРР, NMDA and glutamate could promote binding of (3Н)-МК-801 or (3Н)-ТСР and 
raise its rate of release, antagonist produced an opposite effect (LePage et al., 2005). Thus, the 
non-competitive antagonists such as РСР, etc., were bond with РСР binding sites located deeply in ion 
channel to block calcium channel coupled with NMDA receptor and inhibit calcium ion influx, thereby 
weakening or antagonizing the effect caused by ЕАА (Excitatory Amino Acid) (Kovacic & 
Somanathan, 2010). МК-801 had been tried on treatment of epilepsy, anxiety neurosis and cerebral 
ischemia, etc., with some curative effects. However, the severe adverse reaction terminated further 
clinical use of MK-801 (Foster & Fagg, 1987). It was hoped to find out effective drugs to treat CNS 
disease by binding to PCP sites of NMDA receptor. 
Moreover, the non-competitive antagonists of NMDA receptor also commonly acted on the 
zinc/magnesium binding sites. Many bivalent cations influenced the effect mediated by NMDA 
receptor to a varying degree, with only Mg2+ and Zn2+ ion having important physiological significance 
(Prorok & Castellino, 1998). Inspecting single ion channel recordings from neurons using radio ligand 
binding experiments proved that Mg2+ and Zn2+ all could inhibit the excitatory effect regulated by 
NMDA receptor, yet their mechanism were different: magnesium ion could accelerate dissociation of  
(3H)- MK-801 or (3H)-ТСР, while zinc ion had an opposite action. However, the two did not influence 
binding of (3Н)-СРР with its binding site (Wong, 1991). These results indicated that the binding sites of 
these two cations were located at different positions: the binding site of magnesium ion was deep in ion 
channel, while the binding site of zinc ion was on surface of NMDA receptor (Monaghan, 1989). 
When the concentration of Mg2+ was lower than that of normal extracellular fluid and there was 
concentration gradient, it could selectively block NMDA receptor. This action was voltage dependent, 
when the membrane potential was more negative, its blockage action was the strongest and appeared 
quickly, so it was non-competitive (Nikolaev et al., 2012). Therefore it was argued that at normal 
resting membrane potential, only a fraction of the reaction caused by low frequency synapse activities 
was mediated by NMDA receptor activation, and only when membrane potential was at a more 
negative value (<-70 mV) and NMDA receptor was fully excited to cause relatively long-time reaction 
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(such as repeated discharging in synapse at high frequency, etc.), Mg2+ in extracellular fluid could exert 
more notable function to hinder it from pathological formation, such as preventing diffusion of foci 
impulse to peripheral normal tissue, formation of LTP and degeneration of neurons, etc., thereby 
regulating normal physiological function of NMDA receptor (Ruppersberg et al., 1994). Above actions 
of Mg2+ were also the physiological basis for its anticonvulsion effect.  
Zn2+ also could selectively block NMDA receptor. Zn2+ of low concentration (1~100 nM) could 
antagonize neuronal excitability in rats caused by NMDA receptor activation, with action appearing 
fast and being reversible but it was not potential dependent, which were different from magnesium ion 
(Monaghan, 1989). 
The physiological and pathological function of Zn2+ in brain are not completely understood yet. Zn2+ 
concentration in hippocampus was the highest, and stimulating neurons in hippocampus by high 
concentration of K+ could lead to substantive release of Zn2+, which may participate in regulation and 
control of excitatory transmission of neurons in hippocampus to exert the function of negative feedback, 
weaken excitatory reaction caused by EAA and excitatory neurotoxic action (Amico-Ruvio et al., 
2011). In contrast, injecting trace of zinc sulfate to hippocampus of rabbits or rats could cause clonic 
convulsion and neuron necrosis (Pei & Koyama, 1986). These results seemed to show Zn2+ at 
physiological concentration could block NMDA receptor and had inhibitory effect on NMDA receptor, 
to regulate normal physiological function of NMDA receptor together with Mg2+. When their 
concentration exceeded physiological concentration, they could also resulted in excitatory effect, or 
even caused convulsion and neuron necrosis (Noh et al., 2015).  
4.2 NMDA Receptor & Epilepsy 
In fact, not only AMPA receptor are important in epilepsy, NMDA receptor also plays a role in epilepsy 
development. The change of NMDA receptor was detected after epilepsy occurrence. The 
over-expression and over-activation of NMDA receptor may accounted for epilepsy development. 
Under some pathological conditions, the excessive amount of glutamate in cell can over activate 
NMDA receptors, then endogenous Mg2+ was removed and synchronous depolarization of the 
postsynaptic membrane of many neurons can take place, which resulted in persistent discharge of the 
neuron. Eventually, epilepsy developed with epileptic seizures (Ghasemi & Schachter, 2011). On the 
brain slices of epilepsy animal models and epilepsy patients, the research results for NMDA receptor 
change after epilepsy were different. Zhu et al. (2004) found that 1 hour after injecting with a 
sub-convulsive dose (35 mg/kg) Pentetrazol in abdomen, the amount of GluN2A subunit in cortical 
neuron rose significantly; While 1 hour after injecting with a convulsive dose of (50 mg/kg), the 
amount of GluN2A and GluN2B subunit rose and then gradually reduced till revived to normal state 
after 48 hours, but the expression of GluN1 subunit stayed unchanged. However, Auzmendi et al. (2008) 
stated that injecting convulsant 3-MP (3-mercap- topropionic acid) into rats for four consecutive days 
leading to recurrent epileptic seizures, by immunohistochemistry and immunoblotting technique, they 
could observe the expression of GluN2B subunit in dentate gyrus and parahippocampal gyrus 
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obviously reduced. After injecting 3-MP for 7 consecutive days leading to epilepsy, there was no 
significant difference in GluN2B subunit expression in such areas comparing with the control group. 
On brain slices of intractable epilepsy patients resulted from cortical dysplasia, researchers could see 
significant increase in GluN2B subunit expression by using Western blotting method. Moreover, the 
number of repeat after-discharge of EFP (Epileptiform Field Potentials) increased in “dysplastic” group 
(brain slices with cortical dysplasia) compared with the normal brain slices, where EEP was the 
characteristic expression of later-discharge (Möddel et al., 2005). Such research manifested that the 
GluN2B expression levels on different epilepsy model were different and the GluN2B expression levels 
at different phases of the same epilepsy model were also different, which suggested that GluN2B 
subunit possibly combined with other subunits of NMDA receptor and played a very important role in 
epileptic activity at different phases (Ghasemi & Schachter, 2011).  
The over activated NMDA receptor would lead to a large amount of Ca2+ influx, which resulted in 
calcium overload. As the second messenger of cell signal transduction, Ca2+ could activate PKA 
(protein Kinase A) and PTK (Protein Tyrosine Kinase). Moreover, it bond with CaMK-II (Calmod-
ulin-dependent protein kinase-II), to transduce Ca2+ signal to ERK1/ERK2 (Extracellular 
signal-regulated kinase), where ERK1/ERK2 could be activated under action of some relevant kinase. 
Then the signal was transduced from cell surface to nucleus and caused cell excitotoxicity. The 
excitotoxicity of cortical neuron could led to a series of biochemical change in neuron, which would 
further result in neuron death. (Rogawski, 1992) Meanwhile, the over-activation of NMDA receptor 
would damage mitochondrial membrane potential, which caused obvious increase in amount of 
superoxide. Then oxidative stress injury took place in mitochondrion, which finally resulted in neuronal 
death (Meldrum et al., 1999). Kambe et al. (2008) observed that when hippocampal neurons were 
exposed to large amount of glutamate, the activity of neuronal mitochondria significantly reduced and 
the amount of neuron which had immunoactivity also decreased. However, the immunoactivity of 
cortical neuron and cortical mitochondria were not affected when they were exposed to glutamate. This 
proved that cortical neuron was less sensitive to cell excitotoxicity caused by the over activation of 
NMDA receptor. It deduced that the reason for triggering the phenomenon was because of the 
destruction of mitochondrial membrane potential rather than the intracellular calcium overload. When 
there were epileptic seizures, the increase of Ca2+ would also occur in astrocyte (Rogawski, 1992). On 
the brain slice model of partial epilepsy caused by 4-AP (4-aminopyridine), the increase of neuronal 
excitability would induce the release of neurotransmitter, which caused the increase of Ca2+ in astrocyte, 
and the Ca2+ mediated cell signal would then cause persistent seizures and consequently epilepsy 
development. As a positive-feedback mechanism, epileptic attack facilitated the increase of Ca2+ in 
astrocyte and such continuous increase caused continuous seizures. Thus, the cyclic path between 
neurons and astrocytes was formed (Noebels, 2002). If using Ca2+ chelating agent ВАРТА to inhibit the 
increase of Ca2+ concentration in glial cell, the epileptic symptoms were relieved (Sun et al., 2009). 
This indicated that initial seizure and continuous seizure were relevant to the increase of Ca2+ in 
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astrocytes. 
Epilepsy consists of a group of highly synchronized brain neurons, and it is a disease caused by 
self-limiting abnormal discharge and different reasons. The occurrence of epilepsy links to the 
imbalance of brain excitability and inhibitory neurotransmitter (Sato et al., 1988). Glutamate is the 
most important excitatory neurotransmitter in the central nervous system, widely distributed in the 
central nervous system, closely related to epilepsy. Since NMDA receptor is a glutamate receptor, 
NMDA was over activated when epilepsy developed. Therefore, NMDA receptor antagonists could be 
used in the treatment of paralysis epilepsy. The NMDA receptor antagonist could be competitive or 
non-competitive.  
In the brain tissue of epilepsy patients and animal models, people could see mossy fiber sprouting 
phenomenon in hippocampal granule cell (Dudek & Shao, 2004). Chen et al. (2007) found that on 
chemical kindling and pilocarpine epilepsy model, using selective GluN2A subunit antagonists could 
inhibit the initiation of epilepsy and mossy fiber sprouting, but the selective GluN2B subunit 
antagonists did not work on the beginning of epilepsy and mossy fiber sprouting. Meanwhile, both 
GluN2A subunit antagonists and NR2B subunit antagonists could reduce neuronal death caused by 
status epilepticus. The traditional NMDA receptor antagonist was nonselective and had obvious 
side-effects such as causing mental disorder and dyskinesia. These restricted its clinical applications 
(Ghasemi & Schachter, 2011). The highly efficient GluN2B subunit antagonist could protect CNS from 
CNS degenerative diseases and brain injuries. Even if it was used with large amounts, it had no side 
effects of those of the nonselective NMDA receptor antagonists (Higgins et al., 2016). As a result, it 
was the most widely used clinically. 
For chronic epileptic seizure, GluN2B subunit antagonists also had significant advantages over other 
resistance agents. On brain slice model of chronic epilepsy, Wang and Bausch (2004) compared the 
impact of three kinds of NMDA receptor antagonist on seizures attacked, mossy fiber sprouting and 
neuronal survival. They found that GluN2B subunit antagonist, ifenprodil (GluN2B-selective) and its 
derivatives R025-6981 could reduce epileptic discharges and inhibit mossy fiber sprouting in granulosa 
cells as well as increase neuronal survival of brain slice tissue granular cell layer. The low affinity and 
non-competitive NMDA receptors antagonist memantine, high affinity and competitive NMDA 
receptor antagonist D-APV would accelerate cell mossy fiber sprouting and reduce neuronal survival of 
granular cell and cause epileptic seizures. By long-term D–APV treatment to in vitro hippocampal 
seizure model, Bausch (2006) found D-APV could reduce neuron excitability, and prevent the subjects 
from seizures. However, a sodium channel blocker, tetrodotoxin (TTX) would further increase 
susceptibility to epilepsy. Therefore, plasticity in excitatory synaptic circuits contributed to seizures. 
Hellier et al. (2009) also found that on chronic in vitro kainic acid epilepsy model, application of 
non-selective NMDA receptor antagonist SDZ 220-581 could increase frequency of seizure while using 
R0 25-6981could cause long term inhibitory effect so as to reduce the frequency of seizure. As a result, 
for acute and chronic epileptic seizures, GluN2B subunit antagonists could be used as a selective drug, 
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and had broad clinical application prospects. 
4.3 GluN2B & GluN2A Role in Learning and Memory 
The results indicated that GluN2B was more sensitive to all the 3 fatty acids used than GluN2A, and 
the difference in the characteristics between the GluN2A and GluN2B may accounted for the 
difference. 
Different NMDA receptors formed by different combinations of GluN1 and GluN2 are provided with 
different biological characteristics and participate in different physiological and pathological 
mechanisms. Among them, “GluN2B” was well known as the gene for cleverness for a period of time, 
although both the NMDA receptor containing subunit GluN2A and GluN2B could show the function of 
“dual regulation”: can enhance learning and memorizing via Long-Term Potentiation (LTP), also can 
lead to cognition impairment via Long-Term Depression (LTD) which main symptom is impairment of 
learning and memorizing (Monaghan, 1989). However, GluN2B produced a stronger effect on 
regulating intracellular signaling and cell death signaling, and therefore a greater influence on brain 
function, so it was argued that if GluN2B played a more important role in learning and memory 
compared to GluN2A (Wyllie et al., 2013). Sun et al. (2000) used RT-PCR technology to detect 
expression of subunit of NMDA receptor in olfactory bulb, visual cortex and motor area of adult rats to 
find the subunit GluN2B was mainly distributed in forebrain, especially in cortices. Besides, it was also 
substantively distributed in hippocampus, thalamencephalon and spinal cord, etc. Its distribution in 
these regions provided an important structure base for its physiological function.  
Currently it is known that GluN2B subunit is composed of 1,456 amino acid residues and its molecular 
weight is about 170~180 kDa. Extracellularly, GluN2B has N-terminal signal peptide and four sections 
of transmembrance domain (Ml-M4). M2 is a “channel lining” “loop” facing cytoplasm and reflexing 
toward intramembrane, and serves as the primary structure forming ion channel (Kuner et al., 1996). 
There is a corresponding aspartic acid residue on M2, thereby forming a loop, which is the domain part 
of NMDA receptor ion channel hole and controlled the permeability and conductance of this ion 
channel. Although GluN1 and GluN2 have similar structures (as well as other glutamate receptor 
subunit such as GluA1-4), GluN2 has a larger CTD (C-Terminal Domain), and contains around 600 
amino acids (Maki et al., 2012). Moreover, Martel et al. (2012) stated that CTD of GluN2B promoted 
excitotoxity, as the ion channel with GluN2B opens longer when there was an activation of NMDA 
receptor, which that may resulted in the difference sensitivity to the fatty acids between GluN2A and 
GluN2B. 
When activated, NMDA receptor (GluN2B) is not only permeable to univalent ion Na+ and K+, but is 
also highly permeable to Ca2+ (VanDongen, 2009). Function of NMDA receptor (GluN2B) shows a 
“dual regulation”, high-frequency stimulation can activate NMDA receptor (GluN2B) to phosphorylate 
dense area of postsynaptic membrane via calcium/calmodulin dependent protein kinase П to promote 
formation of LTP (Berberich et al., 2007). Formation of LTP can in turn promote expression of GluN2B 
subunit to form a benign cycle to enhance learning and memorizing (TSUMOTO, 1992). While after 
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NMDA receptor (GluN2B) are activated by low-frequency stimulation, LTD can be formed by 
downstream signaling pathway of non-Ca2+/CaMK-II (Berberich et al., 2007). However, glutamate 
excitotoxicity may happens when NMDA receptor (GluN2B) are over-expressed or over-activated. The 
previous viewpoint is that NMDARs inside and outside synapse have different compositions and 
functions: the intrasynaptic NMDARs are mainly NMDA receptor (GluN2A), which can activate 
CREB (cAMP response element binding protein) and promote expression of BDNF (brain-derived 
neurotro-phic factor) of CREB target gene to protect nerve. The extrasynaptic NMDARs are mainly 
NMDA receptor (GluN2B), which can lower membrane potential of mitochondrial membrane and 
leads to glutamate excitotoxicity (Vizi et al., 2013). Recent research (2013) reported that activation of 
single intrasynaptic or extrasynaptic NMDARs can protect nerve via signaling cascade of CRE & 
BDNF, while the glutamate excitotoxicity depends mainly on co-activation degree and duration of both 
intrasynaptic and extrasynaptic NMDARs. The research also confirmed that both NMDA receptor 
(GluN2A) and NMDA receptor (GluN2B) participated in the “dual regulation”, and NMDA receptor 
(GluN2B) had larger effect on intracellular signaling and cell death signaling regulation, yet with 
mechanism of action was still being controversial (Zhou et al., 2013).  
Decrease of GluN2B subunit in both cortical area and hippocampus showed obvious correlation with 
impairment of learning and memorizing functions (Magnusson, 2010). The rats with GluN2B gene 
knocked out in hippocampus showed cognition impairment such as spatial or non-spatial amnesia, etc. 
(Shipton & Paulsen, 2013). NMDA receptor (GluN2B) in cortical area of prefrontal lobe was also 
important in formation of LTP in cortical area of prefrontal lobe and formation of memory (Wang et al., 
2011). When NMDA receptor (GluN2B) in hippocampus and cortices is activated, cation channel near 
M2 loop will open, extracellular Ca2+ flows in, leading to a rise of intracellular Ca2+concentration, 
finally causing genetic transcription, protein expression and functional change of postsynaptic 
membrane, thereby establishing LTP, which helps learning, memory and cognition (Berberich et al., 
2007).  
Among all subunits of NMDA receptor, the mRNA and protein expression level of GluN2B subunit 
were the most prone to be influenced by age factor (Zamzow et al., 2013). There was an experiment 
showed that high expression level of GluN2B protein in cortices and hippocampus of rats aged 4 
months could promote spatial learning and memory, the GluN2B protein level in forehead cortices and 
hippocampus for rats aged 26 months dropped dramatically and functions of spatial learning and 
memory were damaged. This indicated that GluN2B mRNA and GluN2B protein level in cortices and 
hippocampus showed obvious correlation with age, and also influences spatial learning and memory 
(von Engelhardt et al., 2008). 
For humans, both GluN2A and GluN2B play an important role in the characteristic development of 
cortex. The GluN2B subunit in the brain is rich in the early postnatal period and the GluN2A subunit 
gradually increases with the development (Shipton & Paulsen, 2013). A study done by Bannerman et al. 
(2008) showed that normal Spatial Reference Memory (SRM) in GluN2A-knockout mice was 
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unaffected but fast-access Spatial Working Memory (SWM) was impaired, whereas subcutaneous 
mono-injection of ephedrine (30 mg/kg) upregulated GluN2A subunit expression would like to damage 
SWM. Mathur et al. (2009) studies had shown that systemic administration of selective GluN2B 
antagonist Ro25-6981 can destroy fear memory in rats aged 3 months, and the effect decreased with 
age. GluN2B overexpression in mice showed increased learning and memory (White & Youngentob, 
2004). These studies on different forms of learning and memory emphasized the importance of GluN2 
subunits in learning and memory, and were mainly related to the acquisition of learning and memory. 
Cho et al. (2009) further demonstrated that GluN2A knockout rats could not exhibit 
deprivation-induced depression, but displayed precocious potentiation of the non-deprived eye inputs. 
This study suggested that compensatory enhancement of the sensory input of the non-deprived eye after 
monocular vision deprivation is based on a decrease in GluN2A/2B ratio, and the decrease in ratio was 
achieved by loss of GluN2A subunits. The stimulation frequency of LTP-induced thresholds in GluN2A 
knockout rats was significantly reduced so that the stimulation frequency (1 Hz) induced by Long-Term 
Depression (LTD) in wild-type rats was sufficient to induce LTP.  
It was hypothesized that synapses with a high ratio of GluN2A/GluN2B could induce the production of 
LTD by limiting Ca2+ entry into the cell, that was, if the ratio of GluN2A/GluN2B increased, more 
stimulation (such as high frequency stimulation) was required to induce LTP; While more extensive 
weak stimulation (such as low frequency stimulation) may induce LTD. Conversely, a low 
GluN2A/GluN2B ratio would decrease the LTP induction threshold, making the weaker response to 
elevated Ca2+ and activating CaMKII to induce LTP levels. This was consistent with the hypothesis that 
low NR2A/NR2B ratio favored LTP induction. The NMDA receptor subunit, which regulates 
plasticity-induced effects, has also been studied in other brain regions. Also, the decrease in 
GluN2A/GluN2B could enhance the strengthening of synapses. 
Sensory experience deprivation affects the function of NMDA receptors. For example, after the 24h 
sleeping time was deprived, the expression of GluN1 subunit in hippocampus was decreased and other 
NMDA receptor subunits were not affected. But depriving sleeping time for 4h can enhance GluN2A 
expression (Lebel et al., 2006). Learning and perceived experience could also regulate GluN2B 
changes. Quinlan et al. (2004) found that after 6d olfactory discrimination task training, GluN2B 
protein expression levels of rats decreased and GluN2A protein expression of rats did not change, 
resulting in GluN2A/GluN2B ratio rising. That suggested that piriform cortex NMDA receptors were 
transported. GluN2A/N2B ratio in the brain regions of rats fed in the dark room would like to decrease. 
Compared with other types of NMDA GluN2, the expression and regulation of NMDA receptor 
(GluN2B) are more prone to be influenced by external factors, and it delivers a stronger regulating 
effect on brain function. Thus further research to illuminate the exact action mechanism of NMDA 
receptor (GluN2B) in cognition functions of learning and memorizing and its action mechanism of 
“dual regulation” will be of important significance for exploration into prevention and treatment of 
cognition impairment.  
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4.4 Clinical Use  
Although all of the 3 fatty acids used showed an inhibitory effect on NMDA receptor (both GluN2A 
and GluN2B). The fatty acids only inhibited the function of NMDA receptor (GluN2A) when the 
concentration reached a relatively higher level, and no inhibitory effect found when the concentration 
below 250μM for 4BCCA, 750μM for DA and 200μM for 4EOA. Also, the inhibitory effect on 
GluN2B became smaller when the concentration of the fatty acids used became lower. So, low dose of 
the fatty acids may can be used for epilepsy treatment, without causing side effects, although the dose 
of the fatty acid need to be calculated precisely before put in clinical use and more researches need to 
be done. The most unexpected finding was that there was such an obvious difference between GluN2A 
and GluN2B, and more attention needed to focus on the reason resulted in such a difference. Also, as 
the GluN2B antagonist was always considered as epilepsy treatment, the 3 acids had stronger inhibitory 
effect on GluN2B may also be good to use as GluN2B antagonist to inhibit epileptic attack. 
4.5 Limitations 
However, there were some limitations limited the reliability and validity of the results of the 
experiment. The first was that the fatty acid used not made fresh everytime before the start of one set of 
experiment. In fact, the fatty acids used for testing GluN2B had been running 1-8 months later than 
GluN2A test (GluN2A tests done during NOV 2016-May 2017, GluN2B test done during Jun 2017- 
Aug 2017), in another word, the fatty acids were kept in fridge or freezers for a long period of time. 
Therefore, there was a debate on whether the quality of the fatty acids changed over time, and was that 
change in quality indeed affected the difference in the normalised response between GluN2A and 
GluN2B. Secondly, the solubility of the fatty acids was an obstacle when performing the experiment, as 
the precipitates forms when the concentration of 4BCCA or DA higher than 1mM, and making the 
range to plot the IC50 curve very small, and in the end there was no good way found to plot the IC50 
curve and get the IC50 value. Also, it was hard to know their inhibitory effect on NMDA receptor if 
their concentration higher than 1mM. Thirdly, due to the time limitation, only the highest and lowest 
concentration for 4BCCA, DA, 4EOA tested on GluN2A used for testing GluN2B again to compare the 
difference between the two subunits (100μM and 1mM 4BCCA, 500μM and 1mM DA, 200μM and 
3mM 4EOA used to test their effect on GluN2B), it would be better if try more concentrations, and 
identified the concentration of the corresponding fatty acid which did not cause inhibitory effect on 
GluN2B to compare with GluN2A, and even try to plot the IC50 curve for GluN2B. And lastly, this 
experiment did not show the mechanism of these fatty acids on inhibiting NMDA receptor, and it was 
hard to speculate the mechanism and put the fatty acids in clinical use. 
 
5. Conclusion 
In conclusion, all the 3 fatty acids used in the experiment were non-competitive antagonists, which 
showed inhibitory effect on NMDA recceptor (both GluN2A and GluN2B) when they reached certain 
concentration, although the mechanism was unknown. 4EOA had the strongest inhibitory effect, 
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followed by 4BCCA, and DA had the weakest inhibitory effect. The GluN2B subunit is found to be 
more sensitive than GluN2A subunit to these fatty acids. More researches needed to be done to further 
examine these fatty acids and put them in clinical use, to help and facilitate epilepsy treatment in the 
future. 
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